Enabling healthcare in a digital age – the European Health Data Space
News
23 Apr 2024
Healthcare
Enabling healthcare in a digital age – the European Health Data Space

On Wednesday, 24 April, the European Parliament voted in favour of the European Health Data Space (EHDS). This is a key step to unlock digital health across the European Union and beyond. The EHDS will empower patients and enable more precise and personalised healthcare for improved outcomes across the care spectrum.

The co-legislators’ commitment during the file’s negotiations has strengthened the legislation. This is especially the case regarding the compromise achieved on the opt-out mechanism that recognises citizens’ right to choose whilst also generating representative and quality data for research. This agreement  also improves the digital environment for the testing and certification of electronic health record systems – which aims to avoid bottlenecks caused by third party certification – and enhances support for health professionals’ training and patients’ digital health literacy.

Certain additional elements, namely: greater clarity regarding the definitions of categories of data within scope of secondary use; the exclusion of pre-clinical/exploratory data (eg exploratory research datasets generated by private and public entities to inform early research and development which are not protected by intellectual property rights (IPR)) from secondary use; and more data holder rights around IPR and trade secrets, could have streamlined processes, reduced uncertainty for industry conducting R&D in Europe and strengthened the file.

While the regulation lays a strong foundation, as per the Letta report, there is more to be done, especially to prevent fragmentation during its implementation. The American Chamber of Commerce to the EU remains a committed partner in the digitalisation of the European healthcare landscape, and we will continue to support the EHDS, with keen interest from our member companies to participate in pilot projects.

Related items

News
27 Oct 2025

Advancing EU health policy through competitiveness and innovation

On Monday, 27 October, AmCham EU met with Lorena Boix-Alonso, Deputy Director-General, Directorate-General for Health and Food Safety, European Commission, for an exchange on the role of health policy in strengthening the EU’s competitiveness. The discussion focused on how to foster innovation while ensuring patient safety, as well as ways to streamline the legislative framework to improve efficiency and uphold high standards of care. AmCham EU highlighted the importance of evidence-based, future-proof regulation that supports a resilient health system and drives innovation. Continued dialogue is essential to advancing shared goals for Europe’s health agenda. 

Healthcare
Read more
Read more about Advancing EU health policy through competitiveness and innovation
News
9 Oct 2025

Advancing European healthcare in Strasbourg

From Tuesday, 7 to Wednesday, 8 October, AmCham EU travelled to the European Parliament in Strasbourg, France to engage with MEPs on the future of EU health policy. In meetings with over a dozen policymakers, members underscored the importance of a competitive, innovation-driven life sciences sector that ensures timely patient access to medicines and technologies. The discussions also covered the General Pharmaceutical Legislation, the Medical Devices Regulation, the Critical Medicines Act and the upcoming Biotech Act. The delegation called for evidence-based, proportionate policies that promote regulatory coherence and support Europe’s global leadership in health innovation. 

Healthcare
Read more
Read more about Advancing European healthcare in Strasbourg
How the Critical Medicines Act will strengthen Europe’s life sciences sector
News
4 May 2025

How the Critical Medicines Act will strengthen Europe’s life sciences sector

On Wednesday, 30 April, Thibaut L'Ortye, Senior Director of Public Affairs, AmCham EU, joined a panel discussion on the Critical Medicines Act (CMA). Hosted by the European Policy Centre, Mr L'Ortye underlined the need for open and resilient supply chains to ensure continued access to medicines. He also highlighted the CMA’s potential to strengthen Europe's competitiveness and improve patient access. Avoiding protectionist measures and aligning the CMA with the EU’s wider simplification efforts is essential to attract investment into the Single Market. The discussion highlighted the importance of public-private collaboration to build a more competitive life sciences sector in the EU. 

Healthcare
Read more
Read more about How the Critical Medicines Act will strengthen Europe’s life sciences sector